SC276 / Sana Biotech - LARVOL DELTA

Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates (GlobeNewswire) - "SC291 (HIP-modified CD19-targeted allogeneic CAR T) – We remain on track to file an IND this year. We intend to study this therapy in a range of B cell malignancies and report data beginning next year....SC276 (HIP-modified, CD22/CD19-targeted allogeneic CAR T) – We remain on track for an IND in 2023."

Clinical data • IND • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology

Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting (GlobeNewswire) - "Sana Biotechnology, Inc...announced that preclinical data from its hypoimmune T cell program will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022 in New Orleans, LA....The preclinical data demonstrate these hypoimmunogenic CAR T cells are able to evade both the innate and adaptive arms of the immune system while retaining their antitumor activity....Sana expects to file investigational new drug applications for multiple product candidates that utilize this platform, starting with SC291 (CD19) in 2022 and SC276 (CD19/CD22) as early as 2023."

IND • Preclinical • Oncology • Solid Tumor